Browse
Explore clinical trials and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
87145 trials found · Page 98 of 4358
-
New pill shows promise in slowing advanced breast cancer
Disease control CompletedThis Phase 3 clinical study compares the efficacy and safety of elacestrant to the standard of care (SoC) options of fulvestrant or an aromatase inhibitor (AI) in women and men with breast cancer whose disease has advanced on at least one endocrine therapy including a CDK4/6 inhi…
Phase: PHASE3 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Apr 28, 2026 18:48 UTC
-
New approach aims to shrink tumors before surgery in Hard-to-Treat colon cancer
Disease control Recruiting nowColorectal cancer of Mismatch Repair-deficient (dMMR)/ Microsatellite Instability-high (MSI-H) accounts for approximately 15% of all colorectal cancer patients, with a higher proportion in right colon cancer. Previous studies have found that colon cancer patients with dMMR/MSI-H …
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Apr 14, 2026 13:09 UTC
-
New drug could shield preemies from lifelong lung damage
Prevention Recruiting nowThe purpose of this study is to determine if an investigational drug can prevent Bronchopulmonary Dysplasia, reducing the burden of chronic lung disease in extremely premature infants, as compared to extremely premature infants receiving standard neonatal care alone.
Phase: PHASE2 • Sponsor: OHB Neonatology Ltd. • Aim: Prevention
Last updated Apr 26, 2026 19:36 UTC
-
New Two-Pronged attack tested for tough blood cancer in older adults
Disease control Recruiting nowThis phase II trial studies how well inotuzumab ozogamicin and blinatumomab with or without ponatinib work in treating patients with CD22-positive B-lineage acute lymphoblastic leukemia that is newly diagnosed, has come back after a period of improvement (recurrent), or does not …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 07, 2026 14:36 UTC
-
CAR-T therapy takes on tough lymphoma in major trial
Disease control CompletedThis is a randomized, open label, multicenter phase III trial comparing the efficacy, safety, and tolerability of tisagenlecleucel to Standard Of Care in adult patients with aggressive B-cell Non-Hodgkin Lymphoma after failure of rituximab and anthracycline containing frontline i…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Apr 26, 2026 20:01 UTC
-
New drug combo aims to stop liver Cancer's return after surgery
Disease control OngoingA global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 26, 2026 19:36 UTC
-
Landmark HPV vaccine study shows strong immune response in chinese women and girls
⭐️ VACCINE ⭐️ CompletedThis study investigates the immunogenicity and safety of the 9vHPV vaccine in healthy Chinese females 9 to 45 years of age. The study consists of Stage I (Day 1 to Month 7) and Stage II (post Month 7 to Month 60). Stage II will report the long-term immunogenicity and safety in th…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 26, 2026 20:01 UTC
-
New transplant strategy aims to tame tough blood cancer
Disease control Recruiting nowBackground: Lymphoma is a type of blood cancer. Blood cell transplant can cure some people with lymphoma. Researchers want to see if they can limit the complications transplant can cause. Objective: To test if a stem cell transplant can cure or control lymphoma. Also to test i…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 21, 2026 12:44 UTC
-
New combo therapy shows promise for tough bile duct cancer
Disease control OngoingDurvalumab or Placebo in Combination With Gemcitabine/Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1).
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Apr 24, 2026 16:19 UTC
-
New drug combo shows promise against tough uterine cancer
Disease control CompletedThe purpose of this study is to compare the efficacy of pembrolizumab + lenvatinib to chemotherapy in female participants with Stage III, IV, or recurrent endometrial carcinoma. It is hypothesized that the combination of pembrolizumab + lenvatinib will be superior to chemotherapy…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 26, 2026 19:39 UTC
-
Major trial seeks best strategy to combine powerful new drugs for advanced lung cancer
Disease control OngoingThis phase III trial studies whether pembrolizumab alone as a first-line treatment, followed by pemetrexed and carboplatin with or without pembrolizumab after disease progression is superior to induction with pembrolizumab, pemetrexed and carboplatin followed by pembrolizumab and…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 20, 2026 16:14 UTC
-
Immunotherapy drug shows promise in stopping High-Risk skin cancer recurrence
Disease control CompletedThis is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous cell carcinoma (LA cSCC) that have undergone surgery with curative intent in combination with …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 26, 2026 19:35 UTC
-
New cord blood treatment shows promise for Tough-to-Treat leukemias
Disease control OngoingAllogeneic hematopoietic stem cell transplantation is a life-saving procedure in patients with blood cancers. Cord blood (CB) represents an alternative source of stem cells, which is associated with a lower risk of relapse, especially in the presence of minimal residual disease i…
Phase: PHASE2 • Sponsor: Ciusss de L'Est de l'Île de Montréal • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC
-
Monthly shots show promise for Hard-to-Treat HIV cases
Disease control OngoingThe purpose of this study was to compare the efficacy, safety, and durability of two different strategies to treat participants with a history of sub-optimal adherence and control of their HIV infection: long-acting (LA) antiretroviral therapy (ART) and all-oral standard of care …
Phase: PHASE3 • Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) • Aim: Disease control
Last updated Apr 20, 2026 16:15 UTC
-
Major Alzheimer's drug trial aims to slow memory loss
Disease control OngoingThis study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months…
Phase: PHASE3 • Sponsor: Eisai Inc. • Aim: Disease control
Last updated Apr 01, 2026 14:40 UTC
-
New cocktail shows promise in lung cancer battle
Disease control CompletedThe purpose of this study is to assess the safety and efficacy of pemetrexed + platinum chemotherapy + pembrolizumab (MK-3475) with or without lenvatinib (MK-7902/E7080) as first-line intervention in adults with metastatic nonsquamous non-small cell lung cancer. The primary stud…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Apr 28, 2026 18:49 UTC
-
Massive study tests groundbreaking malaria vaccine in 78,000 african children
⭐️ VACCINE ⭐️ CompletedThe RTS, S/AS01E vaccine was developed to protect children in sub-Saharan Africa from malaria as part of routine immunization programs. This study aims to check the vaccine's safety after it has been introduced. Along with safety, researchers will also assess how well the vaccine…
Sponsor: GlaxoSmithKline • Aim: ⭐️ VACCINE ⭐️
Last updated Apr 17, 2026 16:10 UTC
-
New Immune-Targeting drug joins fight against deadly pancreatic cancer
Disease control OngoingZolbetuximab is being studied as a treatment for people with pancreatic cancer. Most people with pancreatic cancer have a protein called Claudin 18.2 (CLDN18.2) in their tumor. Zolbetuximab is thought to work by attaching to CLDN 18.2 in their tumor. This switches on the body's i…
Phase: PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Apr 13, 2026 20:09 UTC
-
New oral drug shows promise for Tough-to-Treat blood cancers
Disease control CompletedThis is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Phase: PHASE1, PHASE2 • Sponsor: Loxo Oncology, Inc. • Aim: Disease control
Last updated Apr 23, 2026 12:43 UTC
-
Brain cancer trial: does earlier, longer chemo extend life?
Disease control OngoingDue to conflicting data on the optimal moment to start TMZ chemotherapy and the impact of prolongation of the adjuvant phase with TMZ, the ANOCEF (Association des Neuro-Oncologues d'Expression Francophone) group proposes this randomized trial comparing an intensified arm (early T…
Phase: PHASE3 • Sponsor: Centre Oscar Lambret • Aim: Disease control
Last updated Apr 23, 2026 12:44 UTC